Abstract library

234 results for "well-differentiated".
#216 Patients Treated for Well-Differentiated Neuroendocrine Tumors: A Study to Evaluate the Ratio of Patients Lost to Follow-up
Introduction: Well-differentiated neuroendocrine tumors (wdNET) are considered more indolent than other epithelial malignancies. Median survival for patients with G1/G2 NET can range from 33 to 223 months.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Rosine Guimbaud
#971 Well-differentiated Pancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters
Introduction: Well-differentiated (WD) pancreatic neuroendocrine tumors (pNET) are uncommon neoplasms and one challenge lies in predicting tumor behavior and managing these patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Luis Pérez-Casanova
#2152 Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens
Introduction: Well-differentiated NET G3 show a longer clinical course than NEC G3, preliminary data indicate they respond poorly to platinum-based therapies.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Arianna Dal Buono
#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#782 Appendix Well-Differentiated Neuroendocrine Tumors (A-WDNETs) at a Large Tertiary Center: Clinical-Pathological Features and Long-Term Follow-Up Evaluation
Introduction: A-WDNETs comprise 32-57% of appendix tumors, diagnosed incidentally in 0.3-0.9% appendectomies (AP). Overall survival is good, but malignant behavior remains controversial.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. John Preto
#295 Unusual Behavior of Gastric Carcinoid Type 1
Introduction: Gastric carcinoids (GC) are rare tumors of the stomach. GC type 1 are associated with chronic atrophic gastritis (CAG) and are the most benign type, having low metastatic potential.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Matilde P Spampatti
#501 FOLFOX Regimen for Clinically Aggressive Neuroendocrine Tumors: About one Case
Introduction: The treatment for progressive metastatic well-differentiated pancreatic neuroendocrine tumors is based on adriamycin and streptozotocin chemotherapy, which achieves more than 60% tumor regression. However, severe adverse effects are common.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Doctor Leïla Bengrine-Lefevre
#328 Report of Two First-Degree Relatives with Appendix Carcinoid and Review of the Literature
Introduction: Appendix endocrine tumors have an incidence of 2-3 patient/millon/year. They are more common in women, diagnosed incidentally during appendectomies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Claudia Bestani
#1900 Well-Differentiated G1/G2 Pancreatic NETs Can Evolve Towards G3 Tumors
Introduction: Well-differentiated G1/G2 pancreatic NET (pNET) may evolve towards well-differentiated G3 pNET or carcinoma (pNEC)
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Muller Nelly
Authors: Hentic O, Cros J, Rebours V, Zappa M, ...
#1308 Systemic Treaments and Prognostic Factors in Chinese Patients with Progressive Advanced Well-differentiated Pancreatic Neuroendocrine Tumors
Introduction: Patients with well-differentiated pancreatic neuroendocrine tumors (pNETs) often present with metastatic disease at the time of diagnosis when curative surgery is not feasible. A variety of systemic therapeutic options exist, but the best strategy is still unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: Yuejuan Cheng
Authors: Cheng Y, Gao H, Bai C M, Ying H, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.